171 |
Axxess Plus™: The First Drug-Eluting Stent for the Treatment of Bifurcation Lesions |
Jeffrey W. Moses |
May. 19. 06 |
170 |
New Concept and Device for Ostial and Bifurcation Stenting |
Yaron Almagor |
Oct. 06. 05 |
169 |
Drug-Eluting Stents, Late Loss, and Restenosis DES to Prevent MIs |
Richard E. Kuntz |
Sep. 29. 05 |
168 |
What Are the Proper End Points for DES Trials? |
Alan C. Yeung |
Sep. 29. 05 |
167 |
Plaque Progression and Regression |
James R. Margolis |
Sep. 29. 05 |
166 |
Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians |
Gregg W. Stone |
Sep. 29. 05 |
165 |
Is Sirolimus Different from Analogues? |
Robert Falotico |
Sep. 14. 05 |
164 |
Safety and Efficacy of Cypher on Complex Lesion |
Seung-Jung Park |
Sep. 14. 05 |
163 |
REALITY Head-To-Head Comparison |
Alexandre Abizaid |
Sep. 14. 05 |
162 |
Safety and Endeavor II Subsets |
Richard E. Kuntz |
Sep. 14. 05 |